Detalle Publicación

Mechanisms of action for different checkpoint inhibitors

Título de la revista: HEMASPHERE
ISSN: 2572-9241
Volumen: 3
Páginas: 28 - 30
Fecha de publicación: 2019
Take home messages Monoclonal antibodies targeting CTLA-4 enhance the activation of T lymphocytes. The toxicity of these monoclonal antibodies can be reduced targeting the antibody activity to the tumor microenvironment. Monoclonal antibodies targeting the PD-1/PD-L1 axis normalize the effector immune responses in the tumor microenvironment. These monoclonal antibodies are essential drugs for therapeutic combinations due to the excellent safety and efficacy profile of the PD-1/PD-L1 blockade.